Milestone For Bristol Firm Developing Innovative Breast Cancer Detection Product

April 27, 2015

Micrima, the Bristol company developing a safe, low-cost way of improving breast cancer detection, has gained CE marking for its MARIA (Multistatic Array processing for Radiowave Image Acquisition) product, paving the way for further supportive clinical trials in the UK and expansion into Europe.

This European regulatory approval is a significant milestone for the company, originally a spin-out from the University of Bristol, enabling it to stage further supportive clinical trials in preparation for heading its ground-breaking system towards the European market. The non-invasive technology is on track to provide the first true alternative to X-ray mammography for decades.

Micrima executive chairman Roy Johnson said: “Gaining our CE marking is hugely important, proving, as it does, that the firm’s innovative MARIA system complies with all the necessary EU safety, health and environmental requirements.

Read the full article on here.

Why will the CoFund not consider proposals if the Syndicate is already invested?
Read FAQs

Investment Team

Meet the team

We’re pretty sparing with our email comms, but when there are interesting and relevant things happening it’s great to share. If you’d like to receive updates and hear more about what is happening with ACF Investors and the portfolio then please sign up here.

Website by James Dowen Web Designer Web Developer Web design london